



July 15, 2020  
Q3 Newsletter

Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

### Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

[Apply for a Grant](#)

[Contact Us](#)

---

### ARLG Fellowship Opportunities Available

Applications are now being accepted for upcoming fellowships with the ARLG. Infectious disease fellows who are interested in pursuing training, research, and a future career in antibacterial resistance clinical research are encouraged to pursue this competitive opportunity.

The fellowship is a two-year, fully funded program. Participants selected to take part will be offered mentoring from senior ARLG members. They will have the opportunity to receive formal training in epidemiology or statistics at the [Duke University School of Medicine Clinical Research Training Program](#) or an equivalent program at another institution in addition to a clinical research core-training curriculum.


Recipients will also be offered opportunities for integration into the ARLG mission and programs. Funding will be available in July 2021.

To learn more or to submit your application, go to the [ARLG Fellowships page](#).

**The submission deadline is December 1, 2020.**

[Apply Today](#)

## ARLG SPOTLIGHT



**Matthew Kelly, MD, MPH**  
**Asst. Professor of Pediatrics**  
**Program Dir, Pediatric Infectious Diseases Fellowship**  
**Assistant Dir., Duke Pediatric Research Scholars Program**  
**Associate Dir. of Physician-Scientist Development,**  
**Office of Pediatric Education**

### About my role in ARLG

I'm an Assistant Professor of Pediatrics in the Division of Infectious Diseases at Duke University. I'm also a faculty member in the Duke Microbiome Center and the Duke Global Health Institute. I have several leadership roles in the Department of Pediatrics through which I work to support the research training and career development of pediatric residents and fellows who aspire to have research-oriented careers.

I am the lead investigator of the [RESistance In Stem cell Transplant Microbiome \(RESISTOME\) Study](#). This ARLG-funded study seeks to understand risk factors for the acquisition of antibiotic-resistant bacteria among hospitalized children and adolescents.

### About my research

I was awarded an [Early Stage Investigator Seed Grant](#) to conduct the RESistance In Stem cell Transplant Microbiome (RESISTOME) Study. This grant provided support for enrollment of study participants, collection of stool samples, and generation of microbiome sequencing data from these samples.

### Impact of the ARLG funding to my career

My long-term career goal is to develop strategies to prevent and treat infections in children through targeted modification of the microbiome. The support that I received from the ARLG provided me with a number of opportunities for professional development and was critical to my success as I transitioned from fellowship to junior faculty at Duke University.

Read More

## Events

### Dr. Patel Presents President’s Forum at ASM Summer of Science

ARLG Laboratory Center Director and American Society for Microbiology (ASM) President, Robin Patel will be conducting a virtual president’s forum on Thursday, July 16 for ASM Microbe Online’s Summer of Science event.

The virtual events are designed to replace the in-person ASM Microbe 2020 meeting cancelled earlier this year. Selected sessions from all eight scientific tracks will be presented in three parts running from June through August 2020.

Learn more about the ASM Summer of Science [here](#).



Robin Patel, MD

## News

**SUMMARY OF RESULTS** | **MASTER-GC**

The Antimicrobial Resistance Leadership Group (ARLG) funds, designs, and conducts clinical research that will help prevent, diagnose, and treat infections caused by bacteria that are resistant to antibiotics.

The ARLG, along with the team of doctors, scientists, and researchers who ran the study, are pleased to describe the results from a study testing two brand and novel antibiotics and comparing them.

The ARLG appreciates the time and commitment of the research participants who provided samples to this study and is proud to report such an important role in advancing medical science.

**WHAT IS THIS STUDY TITLE?**  
**Effect of the newer antibiotic combination of cloxacillin sodium and dicloxacillin sodium compared to ampicillin sodium and sulbactam sodium for the treatment of community-acquired pneumonia and otitis media in outpatients**

**WHAT IS THE PURPOSE OF THE RESEARCH?**  
 The purpose of the study was to look at whether the newer antibiotic combination was as good as the older antibiotic combination for treating community-acquired pneumonia and otitis media.

**WHAT IS THIS RESEARCH IMPROVING?**  
 Community-acquired pneumonia and otitis media are common infections. It is important to know whether the newer antibiotic combination is as good as the older antibiotic combination for treating these infections. This study was designed to help answer these questions.

Changes to your healthcare should not be made based on information in this summary without first consulting a doctor. If you have questions about these results, speak with your doctor.

**ARLG**

### New Lay Summaries Posted

ARLG has posted two new lay summaries of results. The first covers the Master-GC study and the second describes results from the RAPIDS-GN study.

Both summaries are on the ARLG website [here](#). Please review and share with your patients and staff.

**SUMMARY OF RESULTS** | **RAPIDS-GN 2**

The Antimicrobial Resistance Leadership Group (ARLG) funds, designs, and conducts clinical research that will help prevent, diagnose, and treat infections caused by bacteria that are resistant to antibiotics.

The ARLG, along with the team of study doctors, scientists, and researchers, are pleased to describe the results from a study comparing the speed and accuracy of testing methods to getting information to doctors on what antibiotics to prescribe for bloodstream infections.

The ARLG appreciates the time and commitment of the research participants who provided samples to this study and is proud to report such an important role in advancing medical science.

**WHAT IS THIS STUDY TITLE?**  
**Speed, accuracy, and acceptability testing for blood negative bloodstream infection test**

**WHAT IS THE PURPOSE OF THE RESEARCH?**  
 The purpose of the study was to look at whether the newer testing method was as good as the older testing method for getting information to doctors on what antibiotics to prescribe for bloodstream infections.

**WHAT IS THIS RESEARCH IMPROVING?**  
 Bloodstream infections are common infections. It is important to know whether the newer testing method is as good as the older testing method for getting information to doctors on what antibiotics to prescribe for bloodstream infections. This study was designed to help answer these questions.

Changes to your healthcare should not be made based on information in this summary without first consulting a doctor. If you have questions about these results, speak with your doctor.

**ARLG**

## ASM Microbe Call for Proposals

Don't forget! The American Society for Microbiology (ASM) Microbe 2021 call for proposal deadline is August 3, 2020 at 5:00 p.m. ET.



AMERICAN  
SOCIETY FOR  
MICROBIOLOGY

Learn more or submit your proposal [here](#).

---

## COVID-19 Research Opportunity for Healthcare Workers



Healthcare Worker Exposure  
Response & Outcomes

As infection disease specialists, many of you have been on the front lines and behind the scenes working on COVID-19 related activities well before the pandemic became a global problem. This critical work to treat and protect people from COVID-19 may also come with an added physical, emotional, and mental toll on you, your colleagues, and families.

The [Healthcare Worker Exposure Response & Outcomes \(HERO\) Registry](#) invites all people working in health care to share their clinical and life experiences in order to better understand the impact of COVID-19 on healthcare workers. In addition, the HERO Registry provides an opportunity for healthcare workers to participate in clinical research and generate the evidence needed to fight this pandemic.

Please consider joining and sharing this research opportunity with your entire team (respiratory therapists, environmental service workers, nurses, nursing aids, laboratory technicians). All people working in health care can join at <https://www.heroesresearch.org>



## Recent Publications

View the following recent ARLG publications.

Jacobs MR, Good CE, Hujer AM, Abdelhamed AM, Rhoads DD, Hujer KM, Rudin SD, Domitrovic TN, Connolly L, Krause KM, Patel R, Kreiswirth BN, Rojas LJ, Brinkac LM, Fouts DE, van Duijn D, Bonomo RA; for the Antibiotic Resistance Leadership Group. ARGONAUT II Study of the in vitro activity of plazomicin against carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2020 Apr 21;64(5):e00012-20. doi: 10.1128/AAC.00012-20. Print 2020 Apr 21.

King HA, Doernberg SB, Miller J, Grover K, Oakes M, Ruffin F, Gonzales S, Rader A, Neuss MJ, Bosworth HB, Sund Z, Fowler VG Jr., Holland TL. Patients' Experiences with *Staphylococcus aureus* and Gram-Negative Bacterial Bloodstream Infections: A

Qualitative Descriptive Study and Concept Elicitation Phase to Inform Measurement of Patient-Reported Quality of Life. Clin Infect Dis. 2020 May 23;ciaa611. doi: 10.1093/cid/ciaa611. Online ahead of print.

Banerjee R, Komarow L, Virk A, Rajapakse N, Schuetz A, Dylla B, Earley M, Lok J, Kohner P, Ihde S, Cole N, Hines L, Reed K, Garner O, Chandrasekaran S, de St. Maurice A, Kanatani M, Curello J, Arias R, Swearingen W, Doernberg SB, Patel R; for the Antibacterial Resistance Leadership Group. Randomized trial evaluating clinical impact of RAPid IDentification and Susceptibility testing for Gram Negative bacteremia (RAPIDS-GN). Clin Infect Dis. 2020 May 7;ciaa528. doi: 10.1093/cid/ciaa528. Online ahead of print.

Lodise TP, Smith NM, O'Donnell N, Eakin AE, Holden PN, Boissonneault KR, Zhou J, Tao X, Bulitta JB, Fowler Jr VG, Chambers HF, Bonomo RA, Tsuji BT. Determining the Optimal Dosing of a Novel Combination Regimen of Ceftazidime-Avibactam with Aztreonam against NDM-1-producing Enterobacteriaceae Using Hollow Fiber Infection Model. J Antimicrob Chemother. 2020 May 28;dkaa197. doi: 10.1093/jac/dkaa197. Online ahead of print.

Fida M, Cunningham SA, Murphy MP, Bonomo RA, Hujer KM, Hujer AM, Kreiswirth BN, Chia N, Jeraldo PR, Nelson H, Zinsmaster NM, Patel R; and the Antibacterial Resistance Leadership Group. Core Genome MLST and Resistome Analysis of Klebsiella pneumoniae Using a Clinically-Amenable Workflow. Diagn Microbiol Infect Dis. 2020 May;97(1):114996. doi: 10.1016/j.diagmicrobio.2020.114996. Epub 2020 Jan 21.

Duke Clinical Research Institute | 300 West Morgan Street, Suite 800, Durham, NC 27701

[Unsubscribe {recipient's email}](#)

[Update Profile](#) | [About our service provider](#)

Sent by arlg-newsletter@dm.duke.edu powered by



Try email marketing for free today!

**THIS IS A TEST EMAIL ONLY.**

This email was sent by the author for the sole purpose of testing a draft message. If you believe you have received the message in error, please contact the author by replying to this message. Constant Contact takes reports of abuse very seriously. If you wish to report abuse, please forward this message to [abuse@constantcontact.com](mailto:abuse@constantcontact.com).